{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:33:14Z","timestamp":1791948794429,"version":"4.3.4"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Obesity and overweight have been suggested as a potential predictor of favorable outcomes in certain malignancies treated with immunotherapy. However, most studies have relied on BMI as a proxy for adiposity, without fully considering the distinct roles of fat and lean tissues. This study aimed to explore the association between body composition and treatment response in colorectal cancer patients receiving neoadjuvant PD-1 inhibitor therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with dMMR\/MSI-H colorectal cancer undergoing neoadjuvant PD-1 blockade were included in this study. Body composition parameters were measured using baseline CT images. Pathological response was assessed using tumor regression grade (TRG). Univariate and multivariate analyses were performed to examine the association between body composition variables (total adipose tissue, visceral adipose tissue, subcutaneous adipose tissue, visceral-to-subcutaneous adipose tissue ratio, and skeletal muscle) and pathological complete response (pCR) rates. Correlation analysis was conducted to detect the relationship between body composition and lipid profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 84 patients were included in the analysis. Patients with poor treatment response exhibited significantly lower levels of visceral adipose tissue (VAT), total adipose tissue (TAT), and BMI. On multivariate analysis, higher VAT volume and elevated circulating lymphocyte count were independently associated with increased pCR rates. The positive association between VAT and treatment response was consistent across most subgroups except in patients aged \u2265 65, where the effect tended to be reversed. Additionally, VAT volume correlated positively with triglycerides and negatively with high-density lipoprotein cholesterol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Higher visceral adipose tissue volume is associated with improved pathological complete response in dMMR\/MSI-H colorectal cancer patients treated with PD-1 inhibitors. However, this favorable effect of visceral adiposity may be diminished or reversed in elderly patients (\u2265 65 y), highlighting the potential influence of aging on the metabolic-immune interplay in immunotherapy response.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1589869","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:43:00Z","timestamp":1748583780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of body composition on pathological response to neoadjuvant immunotherapy in dMMR\/MSI-H colorectal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Ziyang","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E-er-man-bie-ke","family":"Jin-si-han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaopu","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanmiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.024","article-title":"LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study","volume":"34","author":"Shiu","year":"2023","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00189","article-title":"Microsatellite instability testing using next-generation sequencing data and therapy implications","volume":"1","author":"Haraldsdottir","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability\u2013high\/mismatch repair\u2013deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1044353","article-title":"Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","article-title":"Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study","volume":"40","author":"Verschoor","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3505","article-title":"Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high\/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01216-3","article-title":"Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"7","author":"Mi","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0448","article-title":"Outcomes among patients with or without obesity and with cancer following treatment with immune checkpoint blockade","volume":"5","author":"Yoo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25363","article-title":"Immunotherapy and overall survival among patients with advanced non\u2013small cell lung cancer and obesity","volume":"7","author":"Ihara","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcancer.2023.02.010","article-title":"Obesity and immune-checkpoint inhibitors in advanced melanoma: A meta-analysis of survival outcomes from clinical studies","volume":"91","author":"Roccuzzo","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000725","article-title":"Obesity diminishes response to PD-1-based immunotherapies in renal cancer","volume":"8","author":"Boi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s13679-023-00497-1","article-title":"Obesity paradox: fact or fiction","volume":"12","author":"Simati","year":"2023","journal-title":"Curr Obes Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol - Cell Physiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00267","article-title":"The immune landscape of visceral adipose tissue during obesity and aging","volume":"11","author":"Khan","year":"2020","journal-title":"Front Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.10.049","article-title":"Inflammatory markers and loss of muscle mass (sarcopenia) and strength","volume":"119","author":"Schaap","year":"2006","journal-title":"Am J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.03.015","article-title":"Inflammation induced loss of skeletal muscle","volume":"80","author":"Londhe","year":"2015","journal-title":"Bone"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0751","article-title":"Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy","volume":"25","author":"Bilen","year":"2020","journal-title":"Oncologist"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.16042","article-title":"The effects of myosteatosis on skeletal muscle function in older adults","volume":"12","author":"Dondero","year":"2024","journal-title":"Physiol Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.957527","article-title":"Association of body composition with clinical outcome in Chinese women diagnosed with breast cancer","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqac273","article-title":"Association of visceral adipose tissue with postoperative outcome in upper gastrointestinal cancer: a systematic review and meta-analysis","volume":"116","author":"Matsui","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12755","article-title":"Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis","volume":"12","author":"Takenaka","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102839","article-title":"Myosteatosis and prognosis in cancer: Systematic review and meta-analysis","volume":"145","author":"Aleixo","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2017.05.017","article-title":"The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer","volume":"37","author":"McSorley","year":"2018","journal-title":"Clin Nutr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study","volume":"28","author":"Antoun","year":"2010","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2020.05.019","article-title":"Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study","volume":"40","author":"Basile","year":"2021","journal-title":"Clin Nutr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2023","article-title":"Obesity paradox does exist","volume":"36","author":"Hainer","year":"2013","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/archinte.165.1.55","article-title":"The obesity paradox: body mass index and outcomes in patients with heart failure","volume":"165","author":"Curtis","year":"2005","journal-title":"Arch Intern Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-012-0059-5","article-title":"The obesity paradox in chronic disease: facts and numbers","volume":"3","author":"Lainscak","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40519-020-00876-w","article-title":"Obesity paradox and stroke: a narrative review","volume":"26","author":"Forlivesi","year":"2021","journal-title":"Eat Weight Disord - Stud Anorex Bulim Obes"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2032804","article-title":"Reassessing human adipose tissue","volume":"386","author":"Cypess","year":"2022","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129187","article-title":"Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome","volume":"129","author":"Kahn","year":"2019","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2009.00623.x","article-title":"Subcutaneous and visceral adipose tissue: structural and functional differences","volume":"11","author":"Ibrahim","year":"2010","journal-title":"Obes Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/490650","article-title":"Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents","volume":"2011","author":"Bj\u00f8rndal","year":"2011","journal-title":"J Obes"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2018-0014","article-title":"Differential effect of subcutaneous abdominal and visceral adipose tissue on cardiometabolic risk","volume":"33","author":"Sam","year":"2018","journal-title":"Horm Mol Biol Clin Investig"},{"key":"B46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity","volume":"43","author":"Braun","year":"2025","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.847088","article-title":"Adiponectin deficiency enhances anti-tumor immunity of CD8+ T cells in rhabdomyosarcoma through inhibiting STAT3 activation","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1397","article-title":"Adiponectin receptor signaling on dendritic cells blunts antitumor immunity","volume":"74","author":"Tan","year":"2014","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.11.009","article-title":"Novel immunomodulatory effects of adiponectin on dendritic cell functions","volume":"11","author":"Tsang","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/29795","article-title":"Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression","volume":"394","author":"Lord","year":"1998","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.01.011","article-title":"A key role of leptin in the control of regulatory T cell proliferation","volume":"26","author":"De Rosa","year":"2007","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001152","article-title":"Leptin augments antitumor immunity in obesity by repolarizing tumor-associated macrophages","volume":"207","author":"Dudzinski","year":"2021","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf039","article-title":"Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study","author":"Schuiveling","year":"2025","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000821","article-title":"Impact of body composition on outcomes from anti-PD1 +\/\u2013 anti-CTLA-4 treatment in melanoma","volume":"8","author":"Young","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122314","article-title":"Deep learning-based body composition analysis predicts outcome in melanoma patients treated with immune checkpoint inhibitors","volume":"11","author":"Faron","year":"2021","journal-title":"Diagnostics"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277708","article-title":"Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors","volume":"18","author":"Makrakis","year":"2023","journal-title":"PloS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13568","article-title":"Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study","volume":"15","author":"Trestini","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S476150","article-title":"Prognostic role of pre-treatment body composition parameters in patients undergoing first-line immunotherapy for metastatic renal cell carcinoma","volume":"16","author":"Lee","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-09345-7","article-title":"Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study","volume":"33","author":"Wang","year":"2023","journal-title":"Eur Radiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235591","article-title":"Association between immune checkpoint inhibitor treatment outcomes and body composition factors in metastatic renal cell carcinoma patients","volume":"15","author":"Takei","year":"2023","journal-title":"Cancers"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2012.04.008","article-title":"Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans","volume":"24","author":"Solana","year":"2012","journal-title":"Semin Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-04752-6","article-title":"Adipose tissue aging: mechanisms and therapeutic implications","volume":"13","author":"Ou","year":"2022","journal-title":"Cell Death Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.726257","article-title":"Prognostic impact of sarcopenia on clinical outcomes in Malignancies treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7753","article-title":"Association of a mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma","volume":"9","author":"Bolte","year":"2023","journal-title":"JAMA Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1218386","article-title":"Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1075593","article-title":"A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Crespin","year":"2023","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"104272","DOI":"10.1016\/j.amsu.2022.104272","article-title":"Acetaminophen: A hazard to immunotherapy","volume":"80","author":"Najeebullah","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI184321","article-title":"The gut microbiome and cancer response to immune checkpoint inhibitors","volume":"135","author":"Gazzaniga","year":"2025","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1589869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:43:01Z","timestamp":1748583781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1589869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2025.1589869"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1589869","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"article-number":"1589869"}}